Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

141 results about "Cortisone" patented technology

Cortisone is a corticosteroid hormone (glucocorticoid). It decreases your body's natural defensive response and reduces symptoms such as swelling and allergic-type reactions. This medication is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin and eye conditions, breathing problems, and certain cancers..

A complete medium for culturing DF-1 cells

The present invention discloses a complete medium for culturing DF-1 cells, including DMEM basal medium 13.7g / L, insulin, non-essential amino acids, transferrin, glutathione, ascorbyl phosphate, sodium selenite, ethanolamine, hydrocortisone, and newborn calf serum. Wherein non-essential amino acids include glycine, alanine, proline, serine, and asparagine. A complete medium for culturing DF-1 cells provided by the present invention can well promote the proliferation of DF-1 cells, can achieve the same proliferation effect as high-concentration fetal bovine serum, and is suitable for the adherent culture of DF-1 cells; using low-concentration newborn calf serum, it is possible to greatly avoid the batch differences, unstable culture results, cytotoxicity, and high risk of carrying pathogens brought by the culture medium with high-concentration serum, narrow application range, expensive fetal bovine serum, and high culture cost; the components are simple, the culture medium preparation process is short in time consumption, the culture efficiency is high, the repeatability is good, and it is suitable for batch production.
Owner:INNER MONGOLIA OPTIMUS BIOTECHNOLOGY CO LTD

Progesterone 5beta-reductase mutant and application thereof in synthesis of 5beta-dihydrosteroid

The invention discloses a progesterone 5beta-reductase mutant and application thereof in synthesis of 5beta-dihydrosteroid, relates to the technical field of biology, and in particular relates to application of gene mining and engineering modification of progesterone 5beta-reductase derived from bacteria in asymmetric synthesis of 5beta-dihydrosteroid. According to the progesterone 5 beta-reductase LpP5beta R disclosed by the invention, the progesterone 5 beta-reductase LpP5beta R from bacteria psoromais is obtained by a gene mining method, and the progesterone 5 beta-reductase LpP5beta R can be subjected to soluble expression in escherichia coli. The mutant obtained by mutating the wild type LpP5beta R has obviously improved catalytic ability on progesterone, and can efficiently catalyze delta 4-3-carbonyl steroids such as hydrocortisone, dinorcitol and the like to generate corresponding 5beta-dihydrosteroids. According to the invention, the technical bottlenecks of poor heterologous expression and low catalytic efficiency of plant-derived progesterone 5beta-reductase are solved, and a potential biocatalyst is provided for green manufacturing of 5beta-dihydrosteroid drugs.
Owner:SHENYANG PHARMA UNIV

Method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma by magnetic bead assisted LC-MS / MS

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.
Owner:ZHEJIANG PROVINCIAL PEOPLES HOSPITAL

Serum-free culture medium for mesenchymal stem cells and use thereof

A serum-free culture medium for mesenchymal stem cells. Specifically, the serum-free culture medium comprises a basic culture medium, a platelet lysate, and other culture components such as but not limited to L-glutamine, hydrocortisone, a growth factor, etc. The serum-free culture medium for stem cells is suitable for two-dimensional culture of mesenchymal stem cells while being especially suitable for three-dimensional culture of mesenchymal stem cells, and has the advantages of high stem cell amplification quality, large quantity, high safety, etc.
Owner:BEIJING CYTONICHE BIOTECH CO LTD

Lung cancer organoid culture medium, culture medium system and culture method thereof

The invention discloses a lung cancer organoid culture medium, a culture medium system and a culture method thereof, the culture medium system comprises an initial culture medium, an amplification culture medium and a differential culture medium, and the initial culture medium comprises an Advanced DMEM / F12 basal culture medium, Glutamax, nicotinamide, R-spondin-1, rhNoggin, FGF-7, FGF-10, B27, Y-27632, A83-01, SB202190 and prostaglandin E2. Hydrocortisone and Forskolin are added into the amplification culture medium; hydrocortisone and dexamethasone are added into the differential culture medium, and the culture medium system is adopted for lung cancer organoid culture. Cells obtained from lung cancer tissues are subjected to primary lung cancer organoid culture in the initial culture medium; then, transferring the obtained lung cancer organoid cells into an amplification culture medium for amplification culture; and then, transferring the lung cancer cells into a differential culture medium for differential culture to obtain the lung cancer organoid.
Owner:HUAXIAYUAN (JIANGSU) BIOTECHNOLOGY CO LTD

Compounds for diagnosing and treating epilepsy syndromes, methods and uses thereof

The present disclosure relates to medical diagnostics and therapeutics, specifically methods and compositions for predicting and preventing Sudden Unexpected Death in Epilepsy (SUDEP) and / or; treating, preventing and / or ameliorating symptoms associated with epileptic seizure syndromes; particularly Dravet Syndrome. It involves the use of biomarkers, selected from cortisol, corticosterone, cortisone, aldosterone, adrenocorticotropic hormone (ACTH), or combinations thereof, to assess SUDEP risk. Additionally, the present subject-matter describes compositions containing cortisone, hydrocortisone, dexamethasone, fludrocortisone, prednisolone, ganaxolone, tetracosactide, adrenocorticotropic hormone (ACTH) or combinations thereof, in a therapeutically effective amount with a pharmaceutically acceptable carrier, adjuvant, or excipient for SUDEP prevention. The disclosure also includes the use of these compositions for treating, preventing, and / or ameliorating seizures in epilepsy patients, particularly those with Dravet Syndrome and / or preventing / predicting SUDEP.
Owner:BIOSTRIKE UNIPESSOAL LDA

Method for constructing and evaluating asthenic stasis toxin type Alzheimer's disease animal model

The invention relates to a construction and evaluation method of an animal model of asthenic stasis toxin type Alzheimer's disease. The model is based on APP / PS1 mice, sleep deprivation, hydrocortisone and carrageenan are used for induction of qi deficiency, kidney deficiency and blood stasis, the total time of modeling is 28 days, and the animal model of the asthenic stasis toxin type Alzheimer disease is obtained. The model is constructed in a multi-factor combination mode, the syndrome characterization is consistent with a clinical observation result, the model is simple, effective and easy to operate, and a reliable experimental carrier can be provided for research and development and action mechanism research of asthenic stasis toxin type Alzheimer disease innovative drugs.
Owner:JIANGSU PROVINCIAL HOSPITAL OF TCM

Combination therapy of clacotelon and minoxidil for use in the treatment of hair loss.

This disclosure provides a method for treating hair loss in a subject requiring treatment for hair loss, comprising topically administering an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil to the subject. This disclosure further provides a topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.
Owner:CASSIOPEA SPA

Preparation method of fluorohydrocortisone acetate

The invention discloses a preparation method of fluorohydrocortisone acetate, and belongs to the technical field of medicine synthesis. According to the method, the fluorine hydrocortisone acetate is obtained through one-step reaction by taking the Anecortisone acetate as an initial raw material and taking a mixture of an organic solvent and water as a solvent under the condition of a Fe (III) reagent and a fluorine reagent. The preparation method disclosed by the invention is simple and convenient to operate, high in safety, mild in reaction condition, low in cost, high in yield, small in corrosivity and suitable for industrial mass production; meanwhile, the problems that in the prior art, operation is inconvenient, corrosivity is high, toxicity is large, dangerousness is high, the requirement for equipment is high, and the yield is low are solved, and a new technical scheme more suitable for industrial production is provided.
Owner:JIANGSU LIANHUAN PHARMA

Topical compositions comprising emulsified povidone iodine solutions and methods of preparation

Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.
Owner:KOJIAN MD JAMES

Detection of corticosteroid efficiency by analysing the rs37973 and rs28362491 polymorphisms

Corticosteroids are currently the only available treatment that provides some benefits to selected patients with septic shock. However, severe side-effects on mortality of hydrocortisone therapy have been reported and there is still an uncertainty of the therapeutic relevancy of hydrocortisone therapy in a number of patients. In this context, the present inventors identified two polymorphic biomarkers that are associated with corticosteroid efficiency independently or in combination. These two polymorphisms, rs2836249 and rs37973, can be detected in patients' blood rapidly and easily, to determine if a corticosteroid treatment would be valuable or inactive in these patients. The present invention therefore provides personalized treatment and diagnostic companion to help establishing the best treatment options for patients suffering from sepsis and potentially from other conditions such as severe asthma, that are treatable with corticosteroids.
Owner:UNIVERSITE DE VERSAILLES SAINT QUENTIN EN YVELINES +2

Method for establishing small animal dilatation pattern model

The invention discloses a method for establishing a small animal dilation line model. Comprising the following steps that an incision is formed in the tail portion of the back skin of a rat, a subcutaneous bag is created below the corium layer of the incision through tweezers, a tissue expander is placed in the incision and close to the position close to the neck and above the vertebra, the subcutaneous bag is closed, and the incision is sewed and closed; smearing the hydrocortisone ointment every day to uniformly cover the skin of the modeling part, and continuously intervening for 3 days; the smearing part is away from the incision part; normal saline is injected into the tissue dilator every day; and taking out the tissue expander after 21 days, standing for 7 days, observing the back condition of the rat, and when the characteristics conforming to early red lines of dilatation lines are observed, indicating that modeling succeeds. The purpose of stretching the skin is achieved by implanting the tissue expander in a small animal body and increasing the size of the tissue expander along with time, and the expansion line generation condition is simulated. The method is simple, convenient to operate and high in success rate.
Owner:THIRD INSTITUTE OF OCEANOGRAPHY STATE OCEANI C ADMINISTRATION +1

Picosterone-17 alpha-propionate for treatment of acne-like rash

The present disclosure provides methods of treating skin acne-like rash in a subject in need thereof. The method comprises applying an effective amount of picosterone-17 alpha-propionate to the surface of the subject. The acne-like rash may include papules, pustules, nodules, scabs, cysts, or any combination thereof on an affected area of the subject. An effective amount of the picosterone-17 [alpha]-propionate can be administered in a surface pharmaceutical formulation comprising the picosterone-17 [alpha]-propionate and one or more pharmaceutically acceptable carriers.
Owner:CASSIOPEA SPA

3-hydroxypyrone derivative as well as preparation method and application thereof

The invention provides a 3-hydroxypyrone derivative as well as a preparation method and application thereof, the compound can effectively inhibit release of proinflammatory cytokines in lipopolysaccharide-induced microglial cells, inhibit release of NO by the lipopolysaccharide-induced microglial cells, inhibit apoptosis of polysaccharide-induced microglial cells, and inhibit apoptosis of lipopolysaccharide-induced microglial cells. The compound has excellent anti-neuroinflammation activity and neuroprotective effect, the activity of the compound is superior to that of positive controls such as curcumin and hydrocortisone, and the compound can be used for preventing and / or treating neuroinflammation and neurodegenerative diseases.
Owner:FUJIAN MEDICAL UNIV

Novel technical method for constructing ovarian cancer organoid

The invention relates to the technical field of biological medicine, and particularly discloses a culture medium formula for constructing ovarian cancer organoid and a culture method. The culture medium comprises the following components: L-glutamine 100x (L-Glutamine), L-glutamine 100x (L-Glutamine), L-glutamine 100x (L-Glutamine 4-hydroxyethylpiperazine ethanesulfonic acid (1M (hepes)); b-27 is free of a serum additive (B27); the preparation method comprises the following steps of: extracting the raw materials, namely nicotinamide; the preparation method comprises the following steps: adding N, N-acetylcysteine amide (N-Acetylcysteine); a forskolin element (Forskolin); and estradiol (beta-Estradiol), which is used for preparing the pharmaceutical composition. A TGF-[beta] inhibitor (A83-01); a p38 MAPK inhibitor (SB202190), and a p38 MAPK inhibitor, a p160ROCK small molecule inhibitor (Y27632); hepatocyte growth factor (HGF); the invention relates to a recombinant human Hergulin beta-1 protein product (Hergulin beta-1) and a preparation method of the recombinant human Hergulin beta-1 protein product. An epidermal growth factor (EGF); a fibroblast growth factor (FGF10); the invention relates to a method for preparing hydrocortisone. The method comprises the following steps: preparing hydrocortisone; and a primary cell antibiotic (Primocin). The culture solution and the culture method have the advantages that ovarian high-grade serous cancer cells can be effectively cultured and induced to develop into organoid. Noggin is not needed in the scheme, and the method is different from a traditional organoid culture method and is low in cost and simple in manufacturing process. Meanwhile, preparation of a conditioned culture medium is not needed, time can be remarkably saved, the situation that the conditioned culture medium is unstable due to too long time is avoided, and the success rate is high and is about 50%.
Owner:FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV +1

Pulmonary arterial hypertension traditional Chinese medicine syndrome model construction method

PendingCN120853960AMedical simulationOrganic active ingredientsBlood gas analysisStaining
The invention discloses a construction method of a pulmonary arterial hypertension traditional Chinese medicine syndrome model, and aims to simulate a pulmonary arterial hypertension animal model with syndrome characteristics of heart-kidney yang deficiency. The method comprises the following steps: inducing rat pulmonary arterial hypertension pathological basis by adopting monocrotaline, and inducing a heart-kidney yang deficiency state in combination with hydrocortisone intervention from the 15th day; the characteristics of the model are evaluated through multiple indexes such as echocardiography, blood gas analysis, tri-gland axis hormone, energy metabolism, renal functions, biochemical factors, HE staining and ultrastructure observation. Results show that the model has pathological changes of pulmonary arterial hypertension and syndromes such as yang deficiency, water retention, life gate fire decline and the like in traditional Chinese medicine, the construction method is stable and repeatable, and the model is suitable for an experimental platform for traditional Chinese medicine intervention research and combination of traditional Chinese medicine and western medicine.
Owner:INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES

Special culture medium for prostate cancer organoid and culture method thereof

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.
Owner:MEIHUI YIJIA FURNITURE CO LTD

Application of phosphatidylserine-hydrocortisone microbubble in preparation of medicine for treating microvascular regeneration after cerebral apoplexy

The invention discloses application of phosphatidylserine-hydrocortisone microvesicles in preparation of a medicine for treating microvascular regeneration after cerebral apoplexy, and relates to the technical field of biomedicine. According to the microbubble, the blood brain barrier can be accurately opened through the ultrasonic vacuolation technology, the medicine can be delivered in a targeted mode, nerve protection and function improvement are accurately evaluated through ultrasonic super-resolution micro blood flow imaging, and microvessel regeneration is accurately regulated and controlled based on H3K18 lactic acid modification.
Owner:ORDOS CENT HOSPITAL +1

A method for constructing an animal model of ovarian reserve function decline with spleen-kidney yang deficiency syndrome and application thereof

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE

Detection system and detection method for cortisol level in urine and application

The invention discloses a system and a method for detecting the level of cortisol in urine and application, and relates to the technical field of detection of the level of cortisol in urine. The detection system comprises a 24h urocortisol related data and urocortisol correlation analysis module. Wherein the 24-hour urocortisol related data and urocortisol correlation analysis module is based on a monitored 24-hour urocortisol level value after a patient takes hydrocortisone acetate, a 24-hour urocortisol related data level value before and 1 hour after the patient takes hydrocortisone acetate at 8 o'clock in the morning, and a 24-hour urocortisol related data level value before and 1 hour after the patient takes hydrocortisone acetate at 4 o'clock in the afternoon; and performing multivariate linear correlation analysis to obtain a linear relation. The urine cortisol level is calculated according to the linear relational expression, the treatment effect of hormone drugs, especially hydrocortisone acetate, on hypopituitary function can be accurately monitored, and the phenomenon that in the prior art, all urine within 24 h is collected and then cortisol detection is conducted, so that the result is not accurate is avoided.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Culture method and culture medium for reducing quantity of differential transcripts of epithelial organoid and in-vivo tissue

The invention relates to a culture method and a culture medium for reducing the number of differential transcripts of epithelial organoid and in-vivo tissues, and solves the technical problems of low growth rate and low formation rate of the organoid in the prior art. The basic components of the culture medium comprise a DMEM / F12 basal culture medium, a penicillin-streptomycin solution, a Glutamax additive, a recombinant spinal protein, a recombinant head protein, Y-27632, an epidermal growth factor, an N-2-hydroxyethyl piperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021, and the additional components of the culture medium comprise a Wnt-3A additive, an ITS-X additive and hydrocortisone. The invention also provides a culture method of the epithelial organoid. The method can be used for culturing epithelial organs.
Owner:PEKING UNIV SCHOOL OF STOMATOLOGY

Compositions and methods for intranasal delivery of hydrocortisone

An intranasal composition generally includes hydrocortisone, a hydrocortisone derivative, or a salt thereof. A method of administering an intranasal composition that includes hydrocortisone, a hydrocortisone derivative, or a salt thereof to a subject. A method of treating adrenal insufficiency in a subject, the method includes administering to a subject, a dose of a composition comprising hydrocortisone, a hydrocortisone derivative, or a salt thereof in an amount effective to treat adrenal insufficiency.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA +4

Biological analysis method for detecting concentration of hydrocortisone butyrate in plasma

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a biological analysis method for detecting the concentration of hydrocortisone butyrate in blood plasma, which is used for analyzing a compound to be detected in the blood plasma through an LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry) method. According to the detection method, a liquid-liquid extraction pretreatment method is preferably adopted, finasteride serves as an internal standard substance, a Shim-pack Velox SP-C18 chromatographic column is adopted, gradient elution and electrospray ionization source tandem mass spectrometry detection are carried out, and the detection method is high in sensitivity, precise, accurate, high in analysis speed, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity and high in sensitivity. The sample analysis requirement in the clinical research of the hydrocortisone butyrate is met.
Owner:HUNAN CORUS PHARM TECH CO LTD

Pyrilutamide combination therapy

The present disclosure provides a method of treating hair loss in a subject in need thereof, comprising topically administering to the subject an effective amount of pyrilutamide in combination with a hair growth-stimulating compound selected from the group consisting of cortexolone-17α-propionate and minoxidil. The present disclosure further provides a topical pharmaceutical formulation comprising pyrilutamide, a hair growth-stimulating compound, and one or more pharmaceutically acceptable carriers.
Owner:CASSIOPEA SPA

An epithelial organoid culture medium and a culture method

The present invention relates to an epithelial organoid culture medium and a culture method, which solve the technical problems of low growth rate and low formation rate of organoids in the prior art. The epithelial organoid culture medium contains basic components and additional components. The basic components include DMEM / F12 basal medium, penicillin-streptomycin solution, Glutamax additive, recombinant spondin, recombinant norrin, Y-27632, epidermal growth factor, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021. The additional components include Wnt-3A, ITS-X additive and hydrocortisone. The present invention also provides a culture method for epithelial organoids. The present invention can be used for the culture of epithelial organoids.
Owner:PEKING UNIV SCHOOL OF STOMATOLOGY

A nociceptor skin organoid chip, its culture medium, construction method and application

The present invention belongs to the technical field of biomedicine, and specifically relates to a nociceptor skin organoid chip and its culture medium, construction method and application. A culture medium for a nociceptor skin organoid chip, the culture medium is composed of fetal bovine serum and the following components added to the fetal bovine serum: epidermal growth factor, bovine pituitary extract, Normocin, B27, nerve growth factor, insulin, hydrocortisone, human brain-derived neurotrophic factor and capsaicin. Using this culture medium to co-culture a skin chip with nociceptors to obtain a nociceptor skin organoid chip, which can be used for the verification of pain perception effects.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

A culture medium and culture method for preparing forest musk gland organoids for musk

The present application relates to the technical field of organoid culture, and specifically discloses a culture medium for musk gland organoids and its preparation method and application. The present application discloses a culture medium, which uses DMEM / F12 as the basic culture medium; contains the following concentrations of components as functional additives: albumin, B‑27, HEPES, glutamine, N‑acetyl‑L‑cysteine, niacinamide, growth factor, Wnt3a, A83‑01, Forskolin, penicillin, streptomycin, hydrocortisone, insulin; the growth factor is EGF and bFGF with a weight ratio of 350: (11‑21). The present application also discloses a method for preparing the above-mentioned culture medium and its application in musk gland organoid culture. The culture medium of the present application can be used to obtain musk gland organoids with stem cell characteristics, and the cell activity is high.
Owner:HEBEI SUPPLY & MARKETING YANSHE BIOTECHNOLOGY CO LTD

Anti-inflammatory piezoelectric hydrogel loaded with mesenchymal stem cells, and preparation method and application thereof

PendingCN123024154ADipeptideGlucocorticoid
The application belongs to the field of osteoarthritis drug research, and discloses an anti-inflammatory piezoelectric hydrogel loaded with mesenchymal stem cells and a preparation method and application thereof. The anti-inflammatory piezoelectric hydrogel loaded with mesenchymal stem cells provided by the application is composed of mesenchymal stem cells, piezoelectric nanotubes, temperature-sensitive hydrogel and glucocorticoids; wherein the mesenchymal stem cells are extracted from SD rat bone marrow mesenchymal stem cells and cultured to the third generation, the piezoelectric nanotubes are formed by self-assembly of phenylalanine dipeptide molecules, the temperature-sensitive hydrogel is prepared by compounding poloxamer 407 and methyl cellulose, and the glucocorticoids can be hydrocortisone sodium succinate, dexamethasone sodium phosphate, betamethasone sodium phosphate and the like. The application further provides a method for extracting and culturing the mesenchymal stem cells, a method for preparing the piezoelectric nanotubes and the temperature-sensitive hydrogel. The anti-inflammatory piezoelectric hydrogel loaded with mesenchymal stem cells is expected to become a new drug in the field of osteoarthritis and has great potential in clinical application.
Owner:ZHENGZHOU UNIV

Substituted 1, 6-dihydropyridinyl-6-phenyl-6-phenyl-1,3-oxazinan-2-one compound

UndeterminedPK141444ADiseaseCortisone
This invention relates to novel compounds of the Formula (1m1) wherein R1, R2, R3, A1, Cy1 and E are as defined in the specification, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds for use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
Owner:VITAE PHARMA INC +1

Hydrocortisone based oral dispersible film and uses thereof

PCT designated stageWO2026052804A1Sheet deliveryPediatric patientDispensary
Orodispersible film (ODF) is an innovative drug formulation that allows for adjustable dosing and improved patient compliance. It is administered into the mouth where it dissolves, making it suitable for children. The present invention provides an optimized ODF gel formulation and an optimal ODF containing therapeutic doses of hydrocortisone-type corticosteroids (HTC). This ODF is thin, flexible and transparent, and suitable for production in hospital pharmacy using standard equipment. The ODF of the invention allows accurate hydrocortisone levels to be released systemically in patients in need thereof, and its good physico-chemical stability is herein demonstrated for several months. This opens up new opportunities for use in pediatric patients, notably for children suffering from congenital adrenal hyperplasia.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3